The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors

Donna M. DiMichele, B. L. Kroner, S. Adair, J. Addiego, V. Anderson, J. Barbosa, P. Blatt, P. Bockenstedt, V. Castle, P. Chenaille, J. Cohen, E. Czapek, J. Davis, G. Davignon, P. De Alarcon, R. Dubowy, Jonathan M Ducore, M. Dugdale, B. Ewenstein, J. FahnerT. John Gribble, D. Gnarra, R. Gruppo, N. Hakami, M. Hanna, W. Hanna, P. Haut, G. Heggie, A. Homans, J. Hutter, C. Johnson, M. Kajani, M. Karpatkin, Casper Kasper, J. Katz, C. Kessler, N. Key, M. Koerper, B. Konkle, R. Kosinski, J. Lazerson, A. Lightsey, T. Loew, J. Lusher, W. MacLaughlin, M. Manco-Johnson, C. Manno, K. McRedmond, P. Phatak, Jerry S Powell, M. Ragni, C. Rosenfield, J. Sanders, P. Santiago-Borrero, P. Saidi, R. Seeler, S. Seremetis, J. Sexauer, S. Travis, L. Valdez, E. Warner, G. White, D. Barrand, J. Drown, J. Herst, M. Inwood, D. Lillicrap, G. Rivard, S. Rubin, H. Stranczyniski, J. Teitel

Research output: Contribution to journalArticle

214 Scopus citations

Abstract

The North American Immune Tolerance Registry was initiated to study of immune tolerance (ITT) in Canada and the United States with respect to: 1) therapeutic regimens in use for haemophilia A (HA) and B (HB) inhibitor patients; 2) therapeutic outcomes; 3) potential predictors of successful outcome and 4) complications of therapy. Data on 188 ITT courses was collected by questionnaire from 60 haemophilia centers from 1993-99. Among the completed courses, the overall ITT success rate was 70% (115/164) for all HA and 31% (5/16) for all HB. Outcome parameters noted to be predictive of ITT success for all HA were 1) pre-ITT induction (p = 0.003), 2) ITT peak (p = 0.007) and 3) historical pre ITT peak (p = 0.04) inhibitors titres. An inverse correlation between total daily dose (units/kg/day) and success: (80% with under 50; 71% with 50-99; 73% with 100-199; and 41% with ≥ 200, p = 0.01) was found. Outcome predictors were not evaluable for HB, although adverse reactions to therapy, including nephrotic syndrome, and access complications were more common among failed courses. Infection most often complicated the use of access catheters. These results are discussed within the context of the international ITT registry and upcoming prospective ITT study.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalThrombosis and Haemostasis
Volume87
Issue number1
StatePublished - 2002
Externally publishedYes

Keywords

  • Hemophilia A
  • Hemophilia B
  • Immune tolerance
  • Inhibitor therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors'. Together they form a unique fingerprint.

  • Cite this

    DiMichele, D. M., Kroner, B. L., Adair, S., Addiego, J., Anderson, V., Barbosa, J., Blatt, P., Bockenstedt, P., Castle, V., Chenaille, P., Cohen, J., Czapek, E., Davis, J., Davignon, G., De Alarcon, P., Dubowy, R., Ducore, J. M., Dugdale, M., Ewenstein, B., ... Teitel, J. (2002). The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87(1), 52-57.